Dr. Cochrane's accomplishments have earned him national and international recognition, and led him to some of North America's most influential scientific and corporate roles in biotechnology.

In 2002, Dr Cochrane received the Queen's Golden Jubilee Medal for his contributions to biotechnology in Canada and the BioAlberta Association Award for his contributions in Alberta. In 2001, the Alberta Science and Technology Leadership Awards Foundation awarded him the Outstanding Contribution to the Alberta Science and Technology Community. He was again recognized nationally in 1999 with the Ottawa Life Sciences Council National Merit Award and in 1992, with the 125th Commemorative Medal from the Government of Canada. In 1977, he received the Queen's Jubilee Medal and in December 1989 he was made an Officer of the Order of Canada.

Originally a graduate of medicine at the University of Toronto, Dr. Cochrane was Professor and Head Pediatrics at Dalhousie Medical School in 1963-67 and helped develop the I.W. Killam Hospital for Children in Halifax. In July 1967 he moved to Alberta, to become founding Dean of Medicine of the Faculty of Medicine at University of Calgary. In July 1973, he served for a year as Deputy Minister of Health Services in Alberta before being appointed President and Vice Chancellor of the University of Calgary in 1974. In late 1978, he assumed a business career as Chairman, President and Chief Executive Officer of Connaught Laboratories Ltd., subsequently acquired by Institute Merieux, Lyon France in 1989.

Dr. Cochrane is President of W.A. Cochrane & Associates Inc., a health products investment consulting company. He is also a Director of companies including: Immune Vaccine Technologies Inc. Halifax; Pheromone Sciences Inc., Toronto (Chairman); Medicure Inc., Winnipeg; University Technologies International Inc., (Chairman), Calgary; Oncolytics Biotech Inc., Calgary; Resverlogix Inc., Calgary; and QSV Biologics Inc., Edmonton. He has also served on the Boards of Monsanto Canada, Connaught Laboratories Ltd., Vasogen Inc. (Chairman), Fluor/Daniel Canada (Chairman), MDS Capital Corp. and the Banff Centre (Chairman).

Dr. Nicholson received his B.Sc. (Physics) and M.D. from the University of Alberta. Dr. Nicholson completed his residency in diagnostic radiology at the Foothills Hospital in Calgary, Alberta and the Royal Victoria Hospital in Montreal, Quebec. He is a member of a number of medical societies including the Royal College of Physicians and Surgeons of Canada and the Alberta Society of Radiologists. Dr. Nicholson has extensive experience in diagnostic radiology and was integral in the widespread adoption of ultrasound in Canada. Dr. Nicholson is widely published and remains clinically active in the areas of echocardiology and fetal/maternal imaging, in addition to being a clinical associate professor in Radiology at University of Calgary Medical School.

Dr. Halliwell has spent the last 40 years studying and advancing the field of medical ultrasound imaging. He currently holds the position of Senior Research Fellow at the University of Bristol Centre for Physics and Engineering in Medicine. Dr. Halliwell is widely published and recognized internationally as both an expert and thought leader in ultrasound imaging.

Alan Knowles served as a director of Company from April 2003 to September 2008. Alan assisted Tim Davies and Richard Evans in forming the Company and continues to assist InnerVision in reaching its funding goals. Alan is a respected Senior Oil and Gas Analyst with Haywood Securities Inc, of Calgary, Canada, a position he has held since October 2000. Between 1996 and 2000, Alan held similar positions with both Research Capital Corporation and Canaccord Capital Corporation. In the 15 years prior to this he held senior financial executive roles with several prominent Canadian public companies. Alan holds a Bachelor of Commerce from the University of Calgary, and both the CMA and CFA designations.